

AMENDMENTS TO THE CLAIMS:

Please cancel claims 53 and 60 without prejudice or disclaimer; amend claims 50-52, 55 and 56; and add claims 62-65. This listing of claims replaces all prior versions and listings of claims in the application.

LISTING OF CLAIMS:

Claims 1-49 (Cancelled).

50. (Currently amended) A sustained release device, comprising an agent that reduces platelet count in a subject, wherein:

the device is adapted for long-term release of the agent is released for at least 7 days;
the agent is released at a rate and in an amount effective to reduce platelet count in a
subject to at least a low normal level but without significantly affecting platelet function; and
the agent is not a myeloproliferative leukemic (MPL) pathway inhibitory agent.

51. (Currently amended) The sustained release device of claim 50, further comprising an agent for treating a vascular disease or complication.

52. (Currently amended) The sustained release device of claim ~~50~~ 51, wherein the agent for treating a vascular disease or complication is selected from ~~the group consisting of~~
among an anti-coagulant agent, a fibrinolytic agent and an inhibitor of platelet function.

53. (Cancelled).

54. (Original) The sustained release device of claim 50, wherein the agent is anagrelide or a derivative of anagrelide.

55. (Currently amended) The sustained release device of claim 50, wherein the agent is released at a rate ranging from ~~30 g/kg/day to 150 g/kg/day~~ 30 µg/kg/day to 150 µg/kg/day.

56. (Currently amended) The sustained release device of claim 50, wherein the agent is released at a rate ranging from ~~1 g/kg/day to 150 g/kg/day~~ 1 µg/kg/day to 150 µg/kg/day.

57. (Original) The sustained release device of claim 50, wherein the agent is released for at least 30 days.

58. (Original) The sustained release device of claim 50, wherein the agent is released for at least 6 months.

59. (Original) The sustained release device of claim 50, wherein the agent is released for at least 1 year.

60. (Original) The sustained release device of claim 50, wherein the agent is released for at least 5 years.

61. (Cancelled).

62. (New) The sustained release device of claim 50, wherein the device is adapted for implantation.

63. (New) A sustained release device, comprising:
a device adapted for long-term delivery of an agent; and
an agent that reduces platelet count in a subject, wherein:

the agent is anagrelide or a derivative of anagrelide; and

the device is adapted for long-term release of the agent for at least 7 days, whereby the anagrelide is released at a rate and dosage that reduces platelet count without significantly affecting platelet function.

64. (New) The device of claim 63, wherein the device is adapted for long-term release of the agent for at least 30 days

65. (New) The device of claim 63, wherein anagrelide is the only active agent.